Summary
341.63 1.07(0.31%)10/04/2024
Cigna Corp. (CI)
Cigna Corp. (CI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.28 | -1.75 | -6.82 | 7.12 | -5.21 | 20.40 | 138.87 | 15,358.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 341.63 | |
| Open | 341.18 | |
| High | 342.21 | |
| Low | 339.32 | |
| Volume | 536,772 | |
| Change | 0.95 | |
| Change % | 0.28 | |
| Avg Volume (20 Days) | 740,038 | |
| Volume/Avg Volume (20 Days) Ratio | 0.73 | |
| 52 Week Range | 253.95 - 370.83 | |
| Price vs 52 Week High | -7.88% | |
| Price vs 52 Week Low | 34.52% | |
| Range | 0.13 | |
| Gap Up/Down | -1.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 96,442 | |
| EBIDTA | 9,216,000,000 | |
| PE Ratio | 28.5800 | |
| PEG Ratio | 0.8920 | |
| WallStreet Target Price | 391.24 | |
| Book Value | 144.9010 | |
| Earnings Per Share | 12.1900 | |
| EPS Estimate Current Quarter | 6.2200 | |
| EPS Estimate Next Quarter | 6.9300 | |
| EPS Estimate Current Year | 28.5100 | |
| EPS Estimate Next Year | 32.1300 | |
| Diluted EPS (TTM) | 12.1900 | |
| Revenues | ||
| Profit Marging | 0.0177 | |
| Operating Marging (TTM) | 0.0081 | |
| Return on asset (TTM) | 0.0308 | |
| Return on equity (TTM) | 0.0897 | |
| Revenue TTM | 204,145,000,448 | |
| Revenue per share TTM | 700.1300 | |
| Quarterly Revenue Growth (YOY) | 0.1930 | |
| Quarterly Earnings Growth (YOY) | -0.1050 | |
| Gross Profit (TTM) | 22,981,000,000 | |
| Dividends | ||
| Dividend Share | 5.0900 | |
| Dividend Yield | 0.0161 | |
| Valuations | ||
| Trailing PE | 28.5800 | |
| Forward PE | 12.3153 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1468 | |
| Revenue Enterprise Value | 0.6268 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 284,073,984 | |
| Shares Float | 282,682,038 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 1.55 | |
| Institutions (%) | 93.21 | |
10/05 09:00 EST - seekingalpha.com
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.4%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.4%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.
10/04 13:16 EST - zacks.com
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
10/03 09:00 EST - prnewswire.com
The Cigna Group's Third Quarter 2024 Earnings Release Details
BLOOMFIELD, Conn. , Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day.
The Cigna Group's Third Quarter 2024 Earnings Release Details
BLOOMFIELD, Conn. , Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day.
10/02 13:20 EST - seekingalpha.com
Dividend Stocks With Strong Q4 Seasonality
Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.
Dividend Stocks With Strong Q4 Seasonality
Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.
10/01 08:05 EST - reuters.com
CVS, Cigna unveil Medicare Advantage plans for 2025
CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.
CVS, Cigna unveil Medicare Advantage plans for 2025
CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.
10/01 06:00 EST - prnewswire.com
Cigna Healthcare Offers Medicare Customers Value, Stability and Choice with 2025 Plans
Plans available for every lifestyle and budget, including Medicare Advantage (MA) plans, Medicare Supplement plans, and standalone Prescription Drug Plans, all with competitive premiums and benefits. Many MA plans available for $0 premium; some give customers money back on their Social Security check.
Cigna Healthcare Offers Medicare Customers Value, Stability and Choice with 2025 Plans
Plans available for every lifestyle and budget, including Medicare Advantage (MA) plans, Medicare Supplement plans, and standalone Prescription Drug Plans, all with competitive premiums and benefits. Many MA plans available for $0 premium; some give customers money back on their Social Security check.
09/26 10:46 EST - zacks.com
Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cigna (CI) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
09/26 10:21 EST - prnewswire.com
The Cigna Group Issues 2024 Vitality In America Report, Revealing Increased Optimism Among Young Americans and Offering Insights on Workforce Health and Engagement
Third annual Vitality In America study shows more people achieving high vitality, driven by improved sense of energy. While Gen Z adults continue to have the lowest overall vitality, they are feeling more confident, capable, and optimistic.
The Cigna Group Issues 2024 Vitality In America Report, Revealing Increased Optimism Among Young Americans and Offering Insights on Workforce Health and Engagement
Third annual Vitality In America study shows more people achieving high vitality, driven by improved sense of energy. While Gen Z adults continue to have the lowest overall vitality, they are feeling more confident, capable, and optimistic.
09/26 07:00 EST - seekingalpha.com
Cigna: This Dividend Grower Could Be Worth Buying Now
The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.
Cigna: This Dividend Grower Could Be Worth Buying Now
The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.
09/24 05:50 EST - fool.com
Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?
The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.
Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?
The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.
09/21 09:00 EST - seekingalpha.com
Our Top 10 Dividend Growth Stocks - September 2024
This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.
Our Top 10 Dividend Growth Stocks - September 2024
This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.
09/20 15:40 EST - benzinga.com
UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?
With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.
UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?
With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.
09/20 14:18 EST - youtube.com
Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
09/20 14:16 EST - prnewswire.com
Express Scripts Comments on FTC's Reckless Insulin Action
Express Scripts was the first to cap out-of-pocket costs for insulin medications at $25 for a 30-day supply in 2019, well before the government took action ST. LOUIS , Sept.
Express Scripts Comments on FTC's Reckless Insulin Action
Express Scripts was the first to cap out-of-pocket costs for insulin medications at $25 for a 30-day supply in 2019, well before the government took action ST. LOUIS , Sept.
09/20 14:02 EST - marketwatch.com
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
09/20 13:37 EST - youtube.com
FTC Sues CVS, Cigna, UnitedHealth Over Insulin Costs
The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.
FTC Sues CVS, Cigna, UnitedHealth Over Insulin Costs
The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.
09/20 13:25 EST - reuters.com
Explainer: Why are US pharmacy benefit managers under fire?
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
Explainer: Why are US pharmacy benefit managers under fire?
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
09/20 12:00 EST - cnbc.com
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.
09/19 12:29 EST - seekingalpha.com
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth.
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth.
09/18 17:22 EST - pymnts.com
Cigna Launches E-Treatment Service for Convenient Patient Access
As the telehealth sector is projected to reach $450 billion by 2032, Cigna Healthcare recently launched an “E-Treatment” option via MDLIVE, offering customers access to urgent care from board-certified doctors without the need for direct phone or video consultations.
Cigna Launches E-Treatment Service for Convenient Patient Access
As the telehealth sector is projected to reach $450 billion by 2032, Cigna Healthcare recently launched an “E-Treatment” option via MDLIVE, offering customers access to urgent care from board-certified doctors without the need for direct phone or video consultations.